SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nastech (NSTK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Terry Kiely who wrote (10)6/3/1997 8:59:00 AM
From: Kip518   of 25
 
Terry, it appears from past comments on this thread that most of us following Nastech are (or have been) clients of Barber & Bronson. They have long recommended this stock (and, I think, may be NSTK's investment banker, as well). B&B's Managing Director, Eric Elliott, has made a couple of appearances on CNBC's Squawk Box, each time mentioning Nastech. The first time the stock had just run down from $20 to $12 after the secondary issue was announced. The secondary was priced at $12 but as you probably know, NTSK continued to slide even more after that (admittedly, along with most micro-caps). Now the climate for microcaps is much better (see today's WSJ & Abbey Cohen's comments) and Eliott's comment yesterday provoked a more positive price action. While there will probably be big overhead resistance in this range my guess is that B&B is committed to getting this stock back up to $20.

Ron
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News